{"groups":[{"description":"Gefitinib 250 mg daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.","id":"FG000","title":"Gefitinib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment Period: May 2004 to October 2006. All recruitment done at The University of Texas MD Anderson Cancer Center."}